RedHill Biopharma Ltd. (RDHL)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Dror Ben-Asher
|
Co-Founder, Chairman & CEO | 591.59k | -- | 1966 |
|
Mr. Razi Ingber
|
Chief Financial Officer | 362.47k | -- | 1984 |
|
Mr. Gilead Raday MPhil, MSc
|
Chief Operating Officer | 303.1k | -- | 1975 |
|
Mr. Adi Frish
|
Chief Corporate & Business Development Officer | 338.13k | -- | 1970 |
|
Mr. Rick D. Scruggs
|
Chief Commercial Officer & Director | 406.3k | -- | 1960 |
|
Dr. Mark L. Levitt M.D., Ph.D.
|
Chief Scientific Officer | -- | -- | -- |
|
Ms. Alexandra Okmian
|
Senior Business Development & Investor Relations Manager | -- | -- | -- |
|
Dr. Reza Fathi Ph.D.
|
Senior Vice President of Research & Development | 299.29k | -- | 1955 |
|
Mr. Guy Goldberg J.D.
|
Chief Business Officer | 338.13k | -- | 1976 |
|
Ms. Patricia Anderson B.Sc. RAC
|
Senior Vice President of Regulatory Affairs | -- | -- | -- |
RedHill Biopharma Ltd.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 13
Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; Rebyota, a microbiota-based therapy for prevention of recurrent Clostridioides difficile infection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. It also commercializes Clenpiq, a ready-to-drink low-volume bowel preparation. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
